These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3493051)

  • 41. Characterisation of centromere (kinetochore) antigen reactive with sera of patients with a scleroderma variant (CREST syndrome).
    Nishikai M; Okano Y; Yamashita H; Watanabe M
    Ann Rheum Dis; 1984 Dec; 43(6):819-24. PubMed ID: 6524984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders.
    Chen ZY; Silver RM; Ainsworth SK; Dobson RL; Rust P; Maricq HR
    Am J Med; 1984 Nov; 77(5):812-22. PubMed ID: 6333815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serological markers in progressive systemic sclerosis: clinical correlations.
    Catoggio LJ; Bernstein RM; Black CM; Hughes GR; Maddison PJ
    Ann Rheum Dis; 1983 Feb; 42(1):23-7. PubMed ID: 6402991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The clinical spectrum of patients with anticentromere antibodies].
    Insua Vilariño S; de la Hera Martínez M; Rodríguez-Valverde V; Merino Pérez J; Alonso Valdivieso JL; Ruiz T
    Rev Clin Esp; 1993 Apr; 192(6):260-4. PubMed ID: 8497719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of anticentromere antibody in idiopathic Raynaud's syndrome.
    Sarkozi J; Bookman AA; Lee P; Keystone EC; Fritzler MJ
    Am J Med; 1987 Nov; 83(5):893-8. PubMed ID: 3314499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The 'CREST' syndrome. Comparison with systemic sclerosis (scleroderma).
    Velayos EE; Masi AT; Stevens MB; Shulman LE
    Arch Intern Med; 1979 Nov; 139(11):1240-4. PubMed ID: 508020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The CREST syndrome associated with the sicca syndrome].
    González Perez JA; Calvo Catala J; Almela Requena JV; González-Cruz Cervellera A; Sospedra Lara EM; Hurtado Vicente MJ
    An Med Interna; 1989 Oct; 6(10):540-2. PubMed ID: 2491051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunological characterization of heterochromatin protein p25beta autoantibodies and relationship with centromere autoantibodies and pulmonary fibrosis in systemic scleroderma.
    Furuta K; Hildebrandt B; Matsuoka S; Kiyosawa K; Reimer G; Luderschmidt C; Chan EK; Tan EM
    J Mol Med (Berl); 1998 Jan; 76(1):54-60. PubMed ID: 9462868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma.
    Akesson A; Wollheim FA
    Br J Rheumatol; 1989 Aug; 28(4):281-6. PubMed ID: 2787182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of a polypeptide associated with coated vesicles and the cytoskeleton which is recognized by a CREST serum.
    Bower DJ; Jeppesen P
    Exp Cell Res; 1986 Nov; 167(1):166-76. PubMed ID: 2875895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Significance of anti-centromere antibodies. Clinical value].
    Meyer O; Haim T; Ryckewaert A
    Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):261-6. PubMed ID: 6348931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of anticentromere antibody in blood relatives of anticentromere positive patients.
    Ruffatti A; Artifoni L; Glorioso S; Calligaro A; Doria A; Gambari P; Todesco S
    J Rheumatol; 1985 Oct; 12(5):940-3. PubMed ID: 3878881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A case of CREST syndrome with rapidly progressive liver damage.
    Yabe H; Noma K; Tada N; Mochizuki S; Nagano M
    Intern Med; 1992 Jan; 31(1):69-73. PubMed ID: 1568046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Anticentromere antibodies. Diagnostic and prognostic value].
    Meyer O; Haïm T
    Nouv Presse Med; 1982 Oct; 11(39):2891-4. PubMed ID: 6755388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infrequency of anticentromere antibody in patients without systemic sclerosis and without Raynaud's phenomenon.
    Migliaresi S; Picillo U; Terri G; Improta RD; La Palombara F; Giordano M
    Arthritis Rheum; 1987 Mar; 30(3):358-9. PubMed ID: 3494456
    [No Abstract]   [Full Text] [Related]  

  • 56. Induction of anticentromere antibody in patients receiving treatment with D-penicillamine.
    Haberhauer G
    Klin Wochenschr; 1989 May; 67(10):535-7. PubMed ID: 2786978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anticentromere antibodies (ACA): clinical distribution and disease specificity.
    Chan HL; Lee YS; Hong HS; Kuo TT
    Clin Exp Dermatol; 1994 Jul; 19(4):298-302. PubMed ID: 7955469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticentromere antibodies in rheumatologic practice are not consistently associated with scleroderma.
    Tubach F; Hayem G; Elias A; Nicaise P; Haim T; Kahn MF; Meyer O
    Rev Rhum Engl Ed; 1997 Jun; 64(6):362-7. PubMed ID: 9513607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Scl 70 antibody--a specific marker of systemic sclerosis.
    Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
    Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticentromere antibody and primary pulmonary hypertension.
    Seibold JR; Trontell MC
    J Rheumatol; 1982; 9(4):607-9. PubMed ID: 6752406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.